Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020

Clicks: 4
ID: 320032
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #256 of 431 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 431 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The most recent assessment of antibodies against measles, mumps, rubella, and varicella-zoster viruses (MeV, MuV, RuV, VZV) in the United States was conducted in 2009–2010. Regular assessments are essential to measure the impact of immunization programs, identify immunity gaps, and inform vaccination strategies. We report updated estimates of national seroprevalence. Methods We used a CDC-developed immunoglobulin G multiplex bead assay to quantitatively detect antibodies against MeV, MuV, RuV, and VZV among participants aged 6–59 years in the 2017–March 2020 National Health and Nutrition Examination Survey. We estimated seroprevalence overall and by sociodemographic characteristics and assessed independent predictors of seropositivity using logistic regression models with weighted procedures for complex survey design. Results Overall seroprevalence was 95.2% (95% CI, 94.0%–96.3%) against MeV, 87.8% (95% CI, 86.5%–89.2%) against MuV, 95.6% (95% CI, 94.5%–96.5%) against RuV, and 97.2% (95% CI, 96.4%–98.0%) against VZV, and remained high across advancing age groups. Younger age and non-Hispanic Black race and ethnicity were independent predictors for MeV, MuV, and RuV seropositivity; sex, birthplace, and health insurance status were independent predictors for seropositivity for at least one of the viruses. Conclusions Nationally, seroprevalence for MeV, MuV, RuV, and VZV antibodies remains high among persons aged 6–59 years and our findings indicate robust antibody responses are maintained decades after vaccination or natural infection. Maintaining high population immunity through vaccination is critical to prevent cases and outbreaks of all four vaccine-preventable diseases.
Reference Key
openalex_W7167680192 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chelsea S. Lutz, Patricia Castro-Roman, Mona Marin, Brian Wakeman, Stephen N. Crooke, Elina El-Badry, Nicole A Escudero Gonzalez, Thomas D. Filardo, Zhizhou Kuang, Daniel L. Joo, Tatiana M. Lanzieri, Sara E. Oliver, Eriko Padron‐Regalado, David Sugerman, Jamie Tappe, Paul A Rota, Tara C. Anderson
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag354
URL
https://doi.org/10.1093/infdis/jiag354
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.